Scott Auerbach
Concepts (385)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Transplantation | 38 | 2025 | 747 | 7.770 |
Why?
| | Heart-Assist Devices | 19 | 2025 | 552 | 3.630 |
Why?
| | Heart Failure | 25 | 2025 | 2234 | 2.770 |
Why?
| | Graft Survival | 10 | 2024 | 534 | 2.020 |
Why?
| | Graft Rejection | 12 | 2024 | 620 | 1.970 |
Why?
| | Muscular Dystrophy, Duchenne | 5 | 2025 | 90 | 1.180 |
Why?
| | Cardiomyopathies | 10 | 2025 | 350 | 1.130 |
Why?
| | Child | 54 | 2025 | 21999 | 1.060 |
Why?
| | Heart Defects, Congenital | 10 | 2025 | 834 | 1.060 |
Why?
| | Transcriptome | 11 | 2025 | 972 | 1.050 |
Why?
| | Gene Expression Profiling | 9 | 2025 | 1774 | 1.040 |
Why?
| | Heart Diseases | 3 | 2023 | 359 | 1.040 |
Why?
| | Liver | 8 | 2024 | 1941 | 1.010 |
Why?
| | Toxicity Tests | 6 | 2025 | 37 | 0.990 |
Why?
| | Toxicogenetics | 5 | 2023 | 6 | 0.900 |
Why?
| | Glomerular Filtration Rate | 2 | 2024 | 745 | 0.850 |
Why?
| | Steroids | 2 | 2015 | 168 | 0.840 |
Why?
| | Carcinogens | 4 | 2022 | 124 | 0.810 |
Why?
| | Myocarditis | 2 | 2023 | 101 | 0.810 |
Why?
| | Child, Preschool | 24 | 2025 | 11080 | 0.730 |
Why?
| | Registries | 15 | 2025 | 2016 | 0.710 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2024 | 612 | 0.700 |
Why?
| | Toxicology | 4 | 2025 | 46 | 0.690 |
Why?
| | Kidney Transplantation | 2 | 2023 | 701 | 0.660 |
Why?
| | Environmental Pollutants | 4 | 2025 | 159 | 0.650 |
Why?
| | Organ Transplantation | 4 | 2024 | 247 | 0.640 |
Why?
| | Adolescent | 34 | 2025 | 21499 | 0.630 |
Why?
| | Small Molecule Libraries | 2 | 2017 | 95 | 0.620 |
Why?
| | Liver Neoplasms, Experimental | 2 | 2018 | 31 | 0.620 |
Why?
| | Humans | 91 | 2025 | 137294 | 0.610 |
Why?
| | Mutagens | 4 | 2019 | 22 | 0.600 |
Why?
| | Kidney Failure, Chronic | 1 | 2023 | 566 | 0.560 |
Why?
| | Retrospective Studies | 22 | 2024 | 15639 | 0.550 |
Why?
| | Exome | 1 | 2018 | 231 | 0.540 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2020 | 389 | 0.540 |
Why?
| | Immunosuppressive Agents | 4 | 2023 | 890 | 0.530 |
Why?
| | Coronary Artery Disease | 2 | 2020 | 703 | 0.520 |
Why?
| | Prosthesis-Related Infections | 1 | 2017 | 95 | 0.520 |
Why?
| | Treatment Outcome | 17 | 2024 | 10800 | 0.510 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2017 | 530 | 0.500 |
Why?
| | Disease Management | 1 | 2020 | 627 | 0.500 |
Why?
| | Extracorporeal Membrane Oxygenation | 4 | 2022 | 292 | 0.500 |
Why?
| | Male | 44 | 2025 | 67560 | 0.500 |
Why?
| | Infant | 19 | 2025 | 9451 | 0.490 |
Why?
| | Cardiomyopathy, Dilated | 4 | 2022 | 383 | 0.480 |
Why?
| | Sequence Analysis, DNA | 1 | 2018 | 812 | 0.470 |
Why?
| | Risk Factors | 15 | 2024 | 10368 | 0.470 |
Why?
| | Cardiology | 1 | 2017 | 278 | 0.460 |
Why?
| | Stroke | 1 | 2023 | 1134 | 0.450 |
Why?
| | High-Throughput Screening Assays | 5 | 2020 | 160 | 0.420 |
Why?
| | Young Adult | 13 | 2024 | 13163 | 0.420 |
Why?
| | Benchmarking | 5 | 2024 | 184 | 0.420 |
Why?
| | Myocardium | 3 | 2022 | 1002 | 0.420 |
Why?
| | Follow-Up Studies | 8 | 2025 | 5125 | 0.410 |
Why?
| | Sequence Analysis, RNA | 2 | 2014 | 452 | 0.390 |
Why?
| | Female | 33 | 2025 | 73052 | 0.380 |
Why?
| | Consensus | 3 | 2025 | 680 | 0.370 |
Why?
| | Histones | 1 | 2017 | 636 | 0.370 |
Why?
| | Risk Assessment | 6 | 2023 | 3439 | 0.350 |
Why?
| | Echocardiography | 3 | 2022 | 659 | 0.340 |
Why?
| | Postoperative Complications | 5 | 2024 | 2658 | 0.340 |
Why?
| | Gene Expression Regulation | 5 | 2025 | 2608 | 0.340 |
Why?
| | Mutation | 2 | 2019 | 3956 | 0.340 |
Why?
| | Delivery of Health Care | 1 | 2017 | 944 | 0.330 |
Why?
| | Dietary Supplements | 3 | 2019 | 562 | 0.330 |
Why?
| | Metabolomics | 4 | 2024 | 679 | 0.330 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2010 | 101 | 0.320 |
Why?
| | Waiting Lists | 4 | 2024 | 262 | 0.320 |
Why?
| | Computational Biology | 4 | 2025 | 646 | 0.320 |
Why?
| | Cimicifuga | 2 | 2019 | 2 | 0.310 |
Why?
| | Plant Preparations | 2 | 2019 | 36 | 0.310 |
Why?
| | Transforming Growth Factor alpha | 1 | 2009 | 57 | 0.310 |
Why?
| | Transplant Recipients | 4 | 2024 | 178 | 0.300 |
Why?
| | Databases, Factual | 5 | 2024 | 1355 | 0.290 |
Why?
| | Genomics | 4 | 2023 | 792 | 0.270 |
Why?
| | Computer Simulation | 4 | 2021 | 979 | 0.260 |
Why?
| | Formaldehyde | 2 | 2018 | 63 | 0.260 |
Why?
| | Transforming Growth Factor beta | 1 | 2009 | 480 | 0.250 |
Why?
| | Plant Extracts | 2 | 2018 | 200 | 0.250 |
Why?
| | DNA Damage | 3 | 2018 | 422 | 0.250 |
Why?
| | Ventricular Function, Left | 3 | 2022 | 540 | 0.250 |
Why?
| | Infant, Newborn | 10 | 2024 | 6054 | 0.240 |
Why?
| | Interleukin-6 | 1 | 2009 | 778 | 0.230 |
Why?
| | Time Factors | 6 | 2025 | 6818 | 0.230 |
Why?
| | Alkanesulfonic Acids | 1 | 2025 | 41 | 0.230 |
Why?
| | Stroke Volume | 4 | 2022 | 619 | 0.220 |
Why?
| | Biotransformation | 1 | 2024 | 66 | 0.220 |
Why?
| | Aflatoxin B1 | 2 | 2014 | 2 | 0.220 |
Why?
| | Kidney | 2 | 2023 | 1467 | 0.220 |
Why?
| | Rats | 9 | 2024 | 5639 | 0.220 |
Why?
| | Animal Testing Alternatives | 2 | 2021 | 2 | 0.220 |
Why?
| | DNA | 2 | 2019 | 1459 | 0.210 |
Why?
| | Multivariate Analysis | 4 | 2019 | 1521 | 0.210 |
Why?
| | Adverse Outcome Pathways | 1 | 2023 | 4 | 0.210 |
Why?
| | Animals | 21 | 2025 | 36862 | 0.210 |
Why?
| | Proportional Hazards Models | 4 | 2019 | 1260 | 0.210 |
Why?
| | Fluorocarbons | 1 | 2025 | 117 | 0.200 |
Why?
| | Vasoplegia | 1 | 2022 | 2 | 0.200 |
Why?
| | Survival Rate | 3 | 2024 | 1970 | 0.200 |
Why?
| | Incidence | 3 | 2020 | 2808 | 0.200 |
Why?
| | Heart Injuries | 1 | 2023 | 37 | 0.200 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2024 | 108 | 0.200 |
Why?
| | Extracellular Vesicles | 1 | 2025 | 145 | 0.200 |
Why?
| | Muscular Dystrophies | 1 | 2022 | 36 | 0.190 |
Why?
| | Hep G2 Cells | 2 | 2025 | 67 | 0.190 |
Why?
| | Rodentia | 1 | 2022 | 56 | 0.190 |
Why?
| | American Heart Association | 2 | 2021 | 306 | 0.190 |
Why?
| | Ginkgo biloba | 2 | 2018 | 8 | 0.190 |
Why?
| | Organisation for Economic Co-Operation and Development | 1 | 2021 | 2 | 0.190 |
Why?
| | Structure-Activity Relationship | 3 | 2017 | 574 | 0.180 |
Why?
| | Hepatocytes | 2 | 2019 | 220 | 0.180 |
Why?
| | Adult | 11 | 2024 | 37724 | 0.180 |
Why?
| | Mutagenicity Tests | 2 | 2019 | 11 | 0.180 |
Why?
| | Clinical Protocols | 1 | 2022 | 268 | 0.180 |
Why?
| | Databases, Chemical | 2 | 2019 | 9 | 0.180 |
Why?
| | Pesticides | 1 | 2021 | 61 | 0.180 |
Why?
| | Coronary Vessels | 2 | 2021 | 246 | 0.170 |
Why?
| | Practice Patterns, Physicians' | 2 | 2021 | 1302 | 0.170 |
Why?
| | Echinacea | 1 | 2019 | 1 | 0.170 |
Why?
| | Adjustment Disorders | 1 | 2019 | 5 | 0.160 |
Why?
| | Age Factors | 4 | 2021 | 3297 | 0.160 |
Why?
| | Quantitative Structure-Activity Relationship | 2 | 2017 | 19 | 0.160 |
Why?
| | Arsenites | 1 | 2019 | 6 | 0.160 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2025 | 2052 | 0.160 |
Why?
| | Stents | 1 | 2023 | 529 | 0.160 |
Why?
| | Cohort Studies | 5 | 2024 | 5726 | 0.160 |
Why?
| | Spironolactone | 1 | 2019 | 36 | 0.160 |
Why?
| | Kaplan-Meier Estimate | 3 | 2017 | 892 | 0.160 |
Why?
| | Logistic Models | 1 | 2024 | 2071 | 0.160 |
Why?
| | United States | 9 | 2022 | 14742 | 0.150 |
Why?
| | Ultrasonography, Interventional | 1 | 2020 | 142 | 0.150 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2019 | 54 | 0.150 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2019 | 327 | 0.150 |
Why?
| | Food Contamination | 1 | 2018 | 48 | 0.150 |
Why?
| | Gene Amplification | 1 | 2019 | 105 | 0.150 |
Why?
| | Eugenol | 1 | 2018 | 4 | 0.150 |
Why?
| | Fontan Procedure | 1 | 2021 | 180 | 0.150 |
Why?
| | Ultrasonography | 2 | 2020 | 752 | 0.150 |
Why?
| | Tissue Fixation | 1 | 2018 | 36 | 0.150 |
Why?
| | Paraffin Embedding | 1 | 2018 | 32 | 0.150 |
Why?
| | Biomarkers | 7 | 2018 | 4164 | 0.150 |
Why?
| | Coronary Angiography | 1 | 2020 | 312 | 0.150 |
Why?
| | DNA, Neoplasm | 1 | 2018 | 164 | 0.140 |
Why?
| | HEK293 Cells | 2 | 2018 | 731 | 0.140 |
Why?
| | Artificial Intelligence | 1 | 2021 | 277 | 0.140 |
Why?
| | Prostate | 1 | 2019 | 175 | 0.140 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 267 | 0.140 |
Why?
| | Mice, Inbred Strains | 1 | 2018 | 409 | 0.140 |
Why?
| | Cryopreservation | 1 | 2018 | 98 | 0.140 |
Why?
| | Cell Culture Techniques | 2 | 2017 | 363 | 0.140 |
Why?
| | Isoantibodies | 1 | 2017 | 60 | 0.140 |
Why?
| | Patient Selection | 1 | 2021 | 692 | 0.130 |
Why?
| | Global Health | 1 | 2020 | 386 | 0.130 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2850 | 0.130 |
Why?
| | Uniparental Disomy | 1 | 2017 | 9 | 0.130 |
Why?
| | Anesthesia, Dental | 1 | 2017 | 22 | 0.130 |
Why?
| | Tooth Extraction | 1 | 2017 | 25 | 0.130 |
Why?
| | Bundle-Branch Block | 1 | 2017 | 31 | 0.130 |
Why?
| | Epigenomics | 1 | 2017 | 115 | 0.130 |
Why?
| | Donor Selection | 1 | 2017 | 77 | 0.130 |
Why?
| | Arsenic | 1 | 2017 | 65 | 0.130 |
Why?
| | Gene Expression | 2 | 2019 | 1501 | 0.130 |
Why?
| | Muscular Diseases | 1 | 2017 | 114 | 0.130 |
Why?
| | DNA Repair | 2 | 2019 | 231 | 0.130 |
Why?
| | Research Design | 2 | 2023 | 1128 | 0.130 |
Why?
| | Education, Medical, Continuing | 1 | 2017 | 128 | 0.130 |
Why?
| | Reproducibility of Results | 3 | 2021 | 3283 | 0.130 |
Why?
| | Depressive Disorder | 1 | 2019 | 380 | 0.130 |
Why?
| | Anesthesia, General | 1 | 2017 | 73 | 0.130 |
Why?
| | HLA Antigens | 1 | 2017 | 237 | 0.130 |
Why?
| | Systems Biology | 1 | 2016 | 66 | 0.120 |
Why?
| | Trisomy | 1 | 2017 | 82 | 0.120 |
Why?
| | Models, Chemical | 1 | 2017 | 268 | 0.120 |
Why?
| | Diagnosis, Differential | 1 | 2020 | 1484 | 0.120 |
Why?
| | Health Services Needs and Demand | 1 | 2017 | 273 | 0.120 |
Why?
| | Neuromuscular Diseases | 1 | 2017 | 122 | 0.120 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2017 | 136 | 0.120 |
Why?
| | Cluster Analysis | 1 | 2017 | 497 | 0.120 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2018 | 767 | 0.120 |
Why?
| | Models, Theoretical | 1 | 2019 | 575 | 0.120 |
Why?
| | Perioperative Care | 1 | 2017 | 181 | 0.120 |
Why?
| | Heme Oxygenase-1 | 1 | 2015 | 64 | 0.120 |
Why?
| | Glucocorticoids | 1 | 2020 | 596 | 0.120 |
Why?
| | Aromatase Inhibitors | 1 | 2015 | 53 | 0.120 |
Why?
| | Gene-Environment Interaction | 2 | 2017 | 194 | 0.120 |
Why?
| | Receptors, Estrogen | 1 | 2018 | 436 | 0.120 |
Why?
| | Pharmaceutical Preparations | 1 | 2017 | 179 | 0.120 |
Why?
| | Equipment Failure | 1 | 2015 | 108 | 0.120 |
Why?
| | RNA, Messenger | 3 | 2024 | 2839 | 0.110 |
Why?
| | Biomarkers, Pharmacological | 1 | 2014 | 28 | 0.110 |
Why?
| | Vaccination | 4 | 2024 | 1379 | 0.110 |
Why?
| | Freezing | 1 | 2014 | 91 | 0.110 |
Why?
| | Rats, Inbred F344 | 1 | 2014 | 264 | 0.110 |
Why?
| | Cell Survival | 1 | 2017 | 1119 | 0.110 |
Why?
| | Crohn Disease | 1 | 2017 | 244 | 0.110 |
Why?
| | Hospitals, Pediatric | 1 | 2017 | 533 | 0.100 |
Why?
| | Cell Membrane | 1 | 2017 | 737 | 0.100 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 1 | 2013 | 25 | 0.100 |
Why?
| | Propensity Score | 1 | 2015 | 290 | 0.100 |
Why?
| | Dexmedetomidine | 1 | 2013 | 44 | 0.100 |
Why?
| | Drug Administration Schedule | 1 | 2015 | 786 | 0.100 |
Why?
| | Proteome | 1 | 2017 | 472 | 0.100 |
Why?
| | Hemodynamics | 2 | 2018 | 1110 | 0.100 |
Why?
| | Epithelial Cells | 1 | 2019 | 1095 | 0.100 |
Why?
| | Disease Progression | 1 | 2020 | 2752 | 0.100 |
Why?
| | Quality Improvement | 1 | 2021 | 1172 | 0.100 |
Why?
| | Genetic Diseases, Inborn | 1 | 2012 | 42 | 0.100 |
Why?
| | Anxiety | 1 | 2019 | 1036 | 0.100 |
Why?
| | Heart | 2 | 2022 | 657 | 0.100 |
Why?
| | Hospitalization | 1 | 2022 | 2214 | 0.090 |
Why?
| | Mental Disorders | 1 | 2020 | 1077 | 0.090 |
Why?
| | Respiratory Insufficiency | 1 | 2015 | 317 | 0.090 |
Why?
| | Models, Genetic | 1 | 2014 | 607 | 0.090 |
Why?
| | Kidney Diseases | 1 | 2015 | 406 | 0.090 |
Why?
| | Patient Acceptance of Health Care | 1 | 2017 | 808 | 0.090 |
Why?
| | Recovery of Function | 1 | 2015 | 657 | 0.090 |
Why?
| | Healthcare Disparities | 1 | 2017 | 652 | 0.090 |
Why?
| | Antibody Formation | 2 | 2022 | 298 | 0.080 |
Why?
| | Oxidative Stress | 1 | 2017 | 1315 | 0.080 |
Why?
| | Prognosis | 3 | 2018 | 4026 | 0.080 |
Why?
| | Carbazoles | 1 | 2010 | 83 | 0.080 |
Why?
| | Pediatrics | 1 | 2018 | 1113 | 0.080 |
Why?
| | Propanolamines | 1 | 2010 | 96 | 0.080 |
Why?
| | Predictive Value of Tests | 2 | 2017 | 2032 | 0.080 |
Why?
| | Signal Transduction | 3 | 2018 | 5078 | 0.080 |
Why?
| | Cell Proliferation | 1 | 2017 | 2479 | 0.080 |
Why?
| | Sensitivity and Specificity | 2 | 2014 | 1946 | 0.080 |
Why?
| | Statistics, Nonparametric | 1 | 2010 | 431 | 0.080 |
Why?
| | Carcinogenicity Tests | 2 | 2022 | 10 | 0.080 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 5769 | 0.080 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 533 | 0.080 |
Why?
| | Multicenter Studies as Topic | 1 | 2010 | 308 | 0.080 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2017 | 1464 | 0.080 |
Why?
| | Antibodies, Viral | 2 | 2024 | 624 | 0.080 |
Why?
| | Survival Analysis | 1 | 2011 | 1321 | 0.070 |
Why?
| | MicroRNAs | 1 | 2015 | 699 | 0.070 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2010 | 323 | 0.070 |
Why?
| | Biological Assay | 2 | 2018 | 123 | 0.070 |
Why?
| | Transplantation, Homologous | 1 | 2009 | 415 | 0.070 |
Why?
| | Cardiomyopathy, Hypertrophic, Familial | 1 | 2007 | 16 | 0.070 |
Why?
| | RNA | 1 | 2014 | 924 | 0.070 |
Why?
| | Neoplasms | 1 | 2022 | 2661 | 0.070 |
Why?
| | Renin-Angiotensin System | 1 | 2007 | 84 | 0.070 |
Why?
| | Receptors, Aryl Hydrocarbon | 2 | 2019 | 56 | 0.070 |
Why?
| | Genotype | 2 | 2009 | 1923 | 0.070 |
Why?
| | Rats, Sprague-Dawley | 2 | 2024 | 2486 | 0.070 |
Why?
| | Polymerase Chain Reaction | 1 | 2009 | 1061 | 0.060 |
Why?
| | Hemofiltration | 1 | 2006 | 30 | 0.060 |
Why?
| | ROC Curve | 2 | 2019 | 548 | 0.060 |
Why?
| | Biopsy | 1 | 2009 | 1127 | 0.060 |
Why?
| | Exons | 2 | 2019 | 351 | 0.060 |
Why?
| | Caprylates | 1 | 2025 | 25 | 0.060 |
Why?
| | Aged | 2 | 2023 | 23851 | 0.060 |
Why?
| | Catheterization, Peripheral | 1 | 2006 | 109 | 0.060 |
Why?
| | Polymorphism, Genetic | 1 | 2007 | 658 | 0.060 |
Why?
| | Catheterization, Central Venous | 1 | 2006 | 111 | 0.050 |
Why?
| | Gene Regulatory Networks | 2 | 2019 | 309 | 0.050 |
Why?
| | Workflow | 1 | 2025 | 166 | 0.050 |
Why?
| | Prospective Studies | 4 | 2020 | 7595 | 0.050 |
Why?
| | Ventricular Outflow Obstruction | 1 | 2023 | 43 | 0.050 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2018 | 2516 | 0.050 |
Why?
| | Organophosphates | 1 | 2024 | 134 | 0.050 |
Why?
| | Cell Line | 2 | 2019 | 2841 | 0.050 |
Why?
| | Everolimus | 1 | 2023 | 91 | 0.050 |
Why?
| | Mycophenolic Acid | 1 | 2023 | 117 | 0.050 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2018 | 537 | 0.050 |
Why?
| | Hypertension, Pulmonary | 1 | 2013 | 1904 | 0.050 |
Why?
| | Vaccines, Synthetic | 1 | 2022 | 126 | 0.050 |
Why?
| | Antibodies | 1 | 2024 | 412 | 0.050 |
Why?
| | Tacrolimus | 1 | 2023 | 199 | 0.050 |
Why?
| | Replantation | 1 | 2021 | 31 | 0.050 |
Why?
| | Bias | 1 | 2022 | 218 | 0.040 |
Why?
| | Insurance Coverage | 1 | 2022 | 229 | 0.040 |
Why?
| | Middle Aged | 2 | 2021 | 33310 | 0.040 |
Why?
| | Data Accuracy | 1 | 2021 | 65 | 0.040 |
Why?
| | Mammals | 1 | 2022 | 286 | 0.040 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 201 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2022 | 217 | 0.040 |
Why?
| | Social Class | 1 | 2022 | 281 | 0.040 |
Why?
| | Cells, Cultured | 2 | 2019 | 4197 | 0.040 |
Why?
| | Exercise Tolerance | 1 | 2022 | 279 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2023 | 1063 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2022 | 5436 | 0.040 |
Why?
| | PPAR alpha | 1 | 2019 | 58 | 0.040 |
Why?
| | Documentation | 1 | 2021 | 191 | 0.040 |
Why?
| | Carcinogens, Environmental | 1 | 2019 | 14 | 0.040 |
Why?
| | Cricetulus | 1 | 2019 | 109 | 0.040 |
Why?
| | CHO Cells | 1 | 2019 | 161 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2019 | 171 | 0.040 |
Why?
| | Chickens | 1 | 2019 | 191 | 0.040 |
Why?
| | DNA Breaks, Double-Stranded | 1 | 2019 | 43 | 0.040 |
Why?
| | Micronucleus Tests | 1 | 2018 | 6 | 0.040 |
Why?
| | Micronuclei, Chromosome-Defective | 1 | 2018 | 7 | 0.040 |
Why?
| | Therapeutic Equivalency | 1 | 2018 | 32 | 0.040 |
Why?
| | Anemia, Megaloblastic | 1 | 2018 | 9 | 0.040 |
Why?
| | Magnetic Resonance Imaging, Cine | 1 | 2019 | 193 | 0.040 |
Why?
| | Hyperplasia | 1 | 2018 | 175 | 0.040 |
Why?
| | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2018 | 43 | 0.040 |
Why?
| | Myocardial Contraction | 1 | 2019 | 340 | 0.040 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2019 | 219 | 0.040 |
Why?
| | Muscular Dystrophy, Emery-Dreifuss | 1 | 2017 | 3 | 0.040 |
Why?
| | Myopathies, Structural, Congenital | 1 | 2017 | 6 | 0.040 |
Why?
| | Muscular Dystrophies, Limb-Girdle | 1 | 2017 | 4 | 0.040 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2019 | 242 | 0.040 |
Why?
| | Activation, Metabolic | 1 | 2017 | 5 | 0.030 |
Why?
| | Barth Syndrome | 1 | 2017 | 8 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2021 | 739 | 0.030 |
Why?
| | Phytotherapy | 1 | 2018 | 83 | 0.030 |
Why?
| | Antidepressive Agents | 1 | 2019 | 235 | 0.030 |
Why?
| | International Cooperation | 1 | 2018 | 199 | 0.030 |
Why?
| | Myotonic Dystrophy | 1 | 2017 | 10 | 0.030 |
Why?
| | HCT116 Cells | 1 | 2017 | 80 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2018 | 184 | 0.030 |
Why?
| | Brazil | 1 | 2017 | 167 | 0.030 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 2017 | 42 | 0.030 |
Why?
| | Infliximab | 1 | 2017 | 111 | 0.030 |
Why?
| | Gastrointestinal Agents | 1 | 2017 | 65 | 0.030 |
Why?
| | Hazardous Substances | 1 | 2016 | 18 | 0.030 |
Why?
| | Folic Acid | 1 | 2018 | 186 | 0.030 |
Why?
| | Death | 1 | 2017 | 118 | 0.030 |
Why?
| | Molecular Conformation | 1 | 2017 | 150 | 0.030 |
Why?
| | Sample Size | 1 | 2017 | 127 | 0.030 |
Why?
| | Databases, Genetic | 1 | 2018 | 237 | 0.030 |
Why?
| | Lab-On-A-Chip Devices | 1 | 2016 | 40 | 0.030 |
Why?
| | United Kingdom | 1 | 2017 | 315 | 0.030 |
Why?
| | Mosaicism | 1 | 2017 | 73 | 0.030 |
Why?
| | Echocardiography, Transesophageal | 1 | 2017 | 101 | 0.030 |
Why?
| | DNA Methylation | 1 | 2021 | 644 | 0.030 |
Why?
| | Friedreich Ataxia | 1 | 2017 | 75 | 0.030 |
Why?
| | Pulsatile Flow | 1 | 2016 | 60 | 0.030 |
Why?
| | Canada | 1 | 2017 | 421 | 0.030 |
Why?
| | Mortality | 1 | 2018 | 361 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1624 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2017 | 564 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2022 | 1274 | 0.030 |
Why?
| | MCF-7 Cells | 1 | 2015 | 124 | 0.030 |
Why?
| | Catheters | 1 | 2015 | 72 | 0.030 |
Why?
| | Colonoscopy | 1 | 2017 | 247 | 0.030 |
Why?
| | Peroxisome Proliferator-Activated Receptors | 1 | 2014 | 17 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2019 | 1985 | 0.030 |
Why?
| | Kidney Tubules, Proximal | 1 | 2015 | 127 | 0.030 |
Why?
| | Cardiotonic Agents | 1 | 2015 | 125 | 0.030 |
Why?
| | Tissue Donors | 1 | 2017 | 417 | 0.030 |
Why?
| | Drugs, Investigational | 1 | 2014 | 33 | 0.030 |
Why?
| | Gene Library | 1 | 2014 | 117 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2015 | 346 | 0.030 |
Why?
| | Organ Specificity | 1 | 2014 | 304 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2017 | 1184 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2021 | 3546 | 0.030 |
Why?
| | Area Under Curve | 1 | 2014 | 315 | 0.030 |
Why?
| | Electrocardiography | 1 | 2017 | 630 | 0.030 |
Why?
| | Glucuronosyltransferase | 1 | 2013 | 16 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2018 | 1250 | 0.030 |
Why?
| | E2F1 Transcription Factor | 1 | 2013 | 64 | 0.030 |
Why?
| | Radiation Effects | 1 | 2012 | 7 | 0.020 |
Why?
| | Genetic Variation | 1 | 2018 | 988 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2013 | 195 | 0.020 |
Why?
| | Erythrocytes | 1 | 2018 | 699 | 0.020 |
Why?
| | Alternative Splicing | 1 | 2014 | 229 | 0.020 |
Why?
| | Acute Disease | 1 | 2015 | 1009 | 0.020 |
Why?
| | Models, Molecular | 1 | 2017 | 1594 | 0.020 |
Why?
| | Estradiol | 1 | 2015 | 518 | 0.020 |
Why?
| | Testosterone | 1 | 2015 | 401 | 0.020 |
Why?
| | Precancerous Conditions | 1 | 2013 | 169 | 0.020 |
Why?
| | Germ-Line Mutation | 1 | 2012 | 172 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2019 | 3414 | 0.020 |
Why?
| | Tobacco Products | 1 | 2012 | 143 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2836 | 0.020 |
Why?
| | Quality of Life | 1 | 2022 | 2885 | 0.020 |
Why?
| | Heart Ventricles | 1 | 2015 | 792 | 0.020 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2013 | 361 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 1162 | 0.020 |
Why?
| | Lung | 1 | 2021 | 4067 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2013 | 1399 | 0.020 |
Why?
| | Echocardiography, Doppler | 1 | 2007 | 109 | 0.020 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2007 | 130 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 2009 | 558 | 0.020 |
Why?
| | DNA Primers | 1 | 2007 | 514 | 0.020 |
Why?
| | Gene Frequency | 1 | 2007 | 521 | 0.020 |
Why?
| | Subclavian Vein | 1 | 2006 | 15 | 0.020 |
Why?
| | Pregnancy | 1 | 2017 | 6743 | 0.010 |
Why?
| | Alleles | 1 | 2007 | 892 | 0.010 |
Why?
| | Base Sequence | 1 | 2007 | 2182 | 0.010 |
Why?
| | Mice | 1 | 2018 | 17774 | 0.010 |
Why?
| | Phenotype | 1 | 2007 | 3202 | 0.010 |
Why?
|
|
Auerbach's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|